欢迎来到天天文库
浏览记录
ID:55061036
大小:171.70 KB
页数:2页
时间:2020-05-08
《原发性肝癌外科治疗的选择-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、248肝胆外科杂志2014年8月第22g,-g4期JournalofHepatobiliarySurgery,Vol,22,No.4,A.201416MuratoreA,ZimmittiG,RiberoD,eta1.Chemothempybetweenthea1.Lancet,2008,371,1007—1016.firstandsecondstagesofatwo—stagehepatectomyforeolorectalliver21NakanoH,OussoultzoglouE,RossoE,eta1.Sinusoidalinjuryincreasemetastases:sho
2、uldweroutinelyrecommenditAnnSurgOncol,2012,morbidityaftermajorhepatectomyinpatientswithcolorectalliverme—19(4):1310—5.tastasesreceivingpreoperativechemotherapy.AnnSurg,2008,24717AbdallaEK.Locoregionalsurgicalandinterventionaltherapiesfor(1):118~24.advancedcoloreetalcancerliverme~stases:expertco
3、nsensusstate.22Vw,spiroC,LaurenceJM,eta1.Asystematicreviewofclini—ments.HPB(Oxford),2013,15(2):119—30.calresponseandsurvivaloutcomesofdownsizingsystemicchemother—18MimaK,BeppuT,ChikamotoA,eta1.Hepaticresectioncombinedapyandrescueliversurgeryinpatientswithinitiallyunreseetablewithradiofrequencya
4、blationforinitiallyunreseetableeolorectallivercolorectallivermetastases.AnnSurgOncol,2012,19:1292—301.metastasesafterefectivechemotherapyisasafeprocedurewithalow23PetrelliF,BamiS.Anti—EGFRagentsforlivermetastases.Resect—incidenceoflocalrecurrence.IntJClinOncol。2013。18:847—55.abilityandoutcomewi
5、thanti—EGFRagentsinpatientswithKRAS19HurwitzH,FehrenbacherL,NovotnyW,eta1.Bevacizmabplusirino—wild-typecolorectalliver-limitedmetastases:ametaanalysis.IntJteca,fluorouracil,andleueovorinformetastaticcolorectalcancer.NewColorectalDis,2012。27:997—1004.EnglJMed,2004,350:2335—2342.24SaiuraA,Yamamot
6、oJ.FavorableOutcomeAfterRepeatResection20NordlingerB.PerioperativechemotherapywithFOLFOX4andsurgeryforColorectalLiverMetastases.AnnSurgOncol,2014.VCPSUSsurgeryaloneforresectablelivermetastasesfromcolorectal(本文编辑耿小平)cancer(EORTCIntergrouptrial40983):arandomisedcontrolledtri—原发性肝癌外科治疗的选择耿小平【关键词】肝
7、癌;外科;治疗【中图分类号】R735.7【文献标识码】c【文章编号】1006-4761(2014)04-0248-02近2O年来恶性肿瘤治疗的重大进展是对不同据就是“无循证医学证据表明患者可能受益即不推恶性肿瘤进行分子和基因分析,在部分肿瘤已形成荐!”典型代表为“巴塞罗那标准”和“米兰标准”。了相对共识的分子和基因分型,针对不同类型选择这两个现行的“权威”标准,分别将肿瘤<3cm肝功不同的化学治疗联合分子靶向药物的治疗方案,取能良好的小肝癌和单个肿瘤<5c
此文档下载收益归作者所有